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ABSTRACT 
Pregnancy is characterised by metabolic changes that occur to support the 
growth and development of the fetus over the course of gestation. These 
metabolic changes can be classified into two distinct phases: an initial 
anabolic phase to prepare an adequate store of substrates and energy which 
are then broken down and used during a catabolic phase to meet the 
energetic demands of the mother, placenta and fetus. Dynamic readjustment 
of immune homeostasis is also a feature of pregnancy and is likely linked to 
the changes in energy substrate utilisation at this time. As cellular 
metabolism is increasingly recognised as a key determinant of immune cell 
phenotype and function, we consider how changes in maternal metabolism 
might contribute to T cell plasticity during pregnancy. 
KEYWORDS: immunometabolism; maternal metabolism; pregnancy; 
Treg; Th2 
INTRODUCTION 
Successful pregnancy involves various maternal adaptations that 
support the fetus [1]. Metabolic changes allow the preferential passage of 
nutrients across the materno-fetal interface for optimal fetal growth and 
development; immune changes ensure tolerance of the fetus [1,2]. 
Maternal metabolic changes during pregnancy are well described in 
tissues such as adipose, liver and skeletal muscle (summarised in Table 1 
and Figure 1). Early pregnancy is characterised by the accretion of 
metabolic substrates in tissues, which is supported by increases in 
maternal energy intake [3,4]. In this anabolic phase, insulin promotes the 
uptake of glucose into tissues where it is either stored [5–7], or in the case 
of adipose tissue, used for lipogenesis [8,9]. In addition to enhanced 
lipogenesis, circulating fatty acids (FA) are taken up by and accumulate in 
maternal adipose tissue [10,11]. Disappearance of amino acids from 
maternal circulation is also characteristic of pregnancy where nitrogen is 
either accreted in maternal tissues or the developing fetus [12–14]. 
However, decreasing insulin sensitivity as pregnancy progresses results in 
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a state of insulin resistance in late pregnancy [15,16]. This promotes a 
catabolic phase of metabolism wherein glucose preferentially passes to the 
developing fetus [7] and lipids are hydrolysed to bring about maternal 
hyperlipidemia [17,18]. Despite gestational changes in glucose utilisation, 
plasma glucose levels are relatively stable throughout pregnancy [5]. 
Failure to establish these metabolic changes is associated with numerous 
gestational complications, such as gestational diabetes mellitus (GDM), 
pre-eclampsia and cholestasis [19–21]. 
 
Figure 1. Overview of maternal substrate utilisation across gestation. (a) During early pregnancy, there 
is increased glucose uptake into surrounding tissues. In adipose tissue, glucose is used for the synthesis of 
triglycerides. Increased breakdown of lipoprotein-triglycerides by lipoprotein lipase results in increased 
uptake of hydrolytic products into adipose tissue, where they are used in lipogenesis. Lipolytic activity of 
adipose tissue is also reduced to promote lipid storage. Amino acids also accumulate in tissues, causing 
hypoaminoacidemia. Transfer of metabolites to the fetus is limited, with amino acids the main contributor. 
During late pregnancy, glucose uptake into maternal tissues is reduced, and preferentially passes across the 
placenta to the fetus. In adipose tissue, there is a switch from lipogenesis to lipolysis. Glycerol and free fatty 
acids (FFA) produced are transferred to lipoproteins, increasing plasma levels of lipoprotein-triglycerides. 
The fate of amino acid metabolism remains largely unchanged from early pregnancy. (b) During early 
pregnancy there is limited availability of circulating amino acids for uptake by immune cells such as T cells. 
In the third trimester, the maternal circulation provides T cells with a fatty-acid rich, amino-acid depleted 
microenvironment. These metabolic conditions could favour Treg and Th2 cell survival and function, as is 
seen during pregnancy. These changes might not be limited to circulating T cells and could underly the 
functions of tissue-resident T cells involved in driving pregnancy-related improvements in rheumatoid 
arthritis and multiple sclerosis. AA, amino acids; FA, fatty acids; TCA, tricarboxylic acid. 
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Table 1. Overview of known metabolic changes that occur during pregnancy. 
Metabolite Change during pregnancy Species Reference 
Glucose 
Plasma glucose concentrations remain at pre-gravid 
levels throughout pregnancy 
Human [5] 
Glucose uptake into maternal tissues decreases in the 
3rd trimester 
Human [7] 
Glucose oxidation is reduced during the 3rd trimester Human [7] 
Increased utilisation of glucose for lipid synthesis, 
which declines rapidly towards the end of pregnancy 
Rat [22] 
Fatty acids (FA) 
Increased accumulation of FAs in adipose tissue in the 
first and second trimester 
Human [11] 
Elevated lipogenesis in maternal tissues during the 
first and second trimester 
Rat [8] 
Increased lipoprotein lipase (LPL) activity during the 
first and second trimester drives FA uptake by 
surrounding tissues 
Human [10] 
Decreased LPL and hepatic lipase activity during the 
third trimester reduces lipid uptake into tissues 
Human [10] 
Increased lipolysis occurs within adipose tissue at the 
end of pregnancy and results in hyperlipidemia 
Rat [18] 




Hypoaminoacidemia occurs early in pregnancy and 
remains throughout 
Human [12,23,24] 
Relative urea production and excretion is reduced 
throughout pregnancy 
Human [13] 
Protein oxidation is reduced at the end of pregnancy Human [25] 
The influence of cellular metabolism on leukocyte phenotype and 
function is an increasingly exciting area of immunology. Mechanisms 
underpinning immune plasticity in pregnancy such as enhanced activity 
of suppressive or regulatory immune cells and increasing susceptibility of 
pregnant women to severe responses to some viral infections such as 
influenza are unknown. Immunometabolism might provide a framework 
for understanding these dynamic adaptations from pre-conception, 
through pregnancy and into the postpartum. Although maternal metabolic 
changes are established in many tissues, it is unknown what effect if any 
there is on immune cells [26]. This review aims to focus on changes to T 
cells, especially the regulatory T (Treg) cell and T helper (Th)2 cell biased 
responses that characterise pregnancy and how changes in maternal 
energy substrate utilisation might link to changes in the activity of these 
cells during pregnancy. 
METABOLISM AND THE IMMUNE SYSTEM 
In addition to the metabolic adaptations that are known to occur 
predominantly in adipose tissue, skeletal muscle and liver, such 
adaptation in the immune system might underpin the immune plasticity 
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that occurs with pregnancy. Altered energy substrate utilisation is 
increasingly understood to dictate immune cell fate and function and 
maternal immunological adaptation might be secondary to the long 
recognised wider metabolic changes that characterise pregnancy. 
Expression and activity of pyruvate kinase is reported to be decreased 
within T cells and neutrophils during normal pregnancy and this will 
decrease the availability of pyruvate within immune cells [27]. This might 
suggest that maternal immune cells downregulate their use of glucose for 
energy substrate production which would alter their function during 
pregnancy. Indeed, cellular metabolic analysis showed reduced glycolysis 
in peripheral blood mononuclear cells (PBMCs) of late pregnant women 
versus non-pregnant women [28]. While this early evidence is suggestive 
of immunometabolic adaptation in pregnancy, we are a long way from 
understanding these processes or elaborating their contribution to 
pregnancy outcome. However, our existing understanding of the 
immunometabolic characteristics of some immune cell types can provide 
insight into mechanisms of plasticity during pregnancy with CD4+/FoxP3+ 
regulatory T (Treg) cells and Th2 cells perhaps the best examples of this. 
CD4+/FOXP3+ REGULATORY T CELLS 
Treg cells are important in the control of self-reactive immune cells to 
maintain immunological self-tolerance [29] and are increased in both the 
decidua and maternal peripheral blood with pregnancy [30,31]. The majority 
of the maternal Treg population consists of effector Treg cells not resulting 
from clonal expansion [32,33]. Reduced numbers of peripheral Treg cells 
have been associated with several adverse pregnancy outcomes including 
recurrent miscarriage and preeclampsia [34,35]. Mouse models of pregnancy 
have demonstrated that Treg cells are required to mediate maternal 
tolerance to the fetus [36]. Their absence is characterised by significant 
lymphocyte infiltration and haemorrhage at the materno-fetal interface, 
which ultimately results in abnormal fetal development and gestational 
failure [36]. Additionally, aberrant Treg function also results in abortion and 
the transfer of Treg cells from healthy pregnancies to these abortion-prone 
mice improves pregnancy outcome [37]. This highlights the important role 
for Treg cell biased responses in ensuring successful pregnancy. 
Maternal Treg cells are likely to play an important role in facilitating 
peripheral immune tolerance as evidenced by improved outcome of some 
autoimmune diseases during pregnancy. For example, decreased disease 
severity and complete remission have been seen in pregnant women with 
rheumatoid arthritis (RA) [38,39]. RA disease severity is inversely 
correlated with maternal Treg cell numbers in humans and Treg cells from 
pregnant mice alleviated disease when transferred into non-pregnant RA 
mice [40,41]. Pregnancy-induced amelioration of multiple sclerosis is 
associated with the expansion and enhanced function of maternal Treg 
cells [42–44]. In contrast maternal Treg cells can confer increased 
susceptibility to infection through their immunosuppressive function [45].  
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Figure 2. The potential effect of maternal metabolism on Treg differentiation and function. Decreased 
extracellular amino acids concentrations combined with increased transforming growth factor-β 
concentrations during pregnancy would enhance the FoxP3-mediated regulatory T cell (Treg) 
differentiation. Short-chain fatty acids amongst the increased maternal extracellular fatty acid pool would 
also enhance Treg differentiation. Increased circulating fatty acid concentrations could increase the 
availability of cellular acetyl-coA. Flux of acetyl-coA through mevalonate metabolism and lipid synthesis is 
vital for Treg function, such as interleukin-10 (IL-10) production, and Treg survival. α-KG, α-ketoglutarate; 
EAAs, essential amino acids; FA, fatty acid; IL-10, interleukin-10; LCFA, long-chain fatty acid, mTOR, 
mechanistic target of rapamycin; SCFA, short-chain fatty acid; TCA, tricarboxylic acid; TGF-β, transforming 
growth factor-β; Treg, regulatory T cell. 
Together, this provides evidence that changes to maternal Treg cell 
function are not limited to the fetal-placental interface but also occur 
systemically during pregnancy and are best exemplified by measures in 
maternal peripheral blood although in humans these observations relate 
predominantly to relative changes in abundance rather than functional 
readouts. However, it remains unknown what the underlying mechanisms 
are that drive increased Treg cell function during pregnancy. Given our 
understanding of the role of metabolism in Treg cell development and 
function more generally, it is likely that the altered metabolism that occurs 
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in normal pregnancy as described above contributes to changes in Treg 
cell function (Figure 2). Metabolism likely interacts with hormone-
dependent and fetal antigen-driven changes to Treg responses in 
pregnancy; indeed placental hormones are key drivers of the metabolic 
adaptations summarised above and in Table 1. Increased Treg numbers 
are common in both allogeneic and syngeneic pregnancies highlighting 
the role of pregnancy hormones [36], with a greater increase in allogeneic 
pregnancies [46], suggesting that fetal alloantigens make a telling 
contribution. While the impact that the local metabolic environment 
might have on Treg fate and function has yet to be elucidated in 
pregnancy, the following subsections will highlight areas of the literature 
that suggest it could contribute to gestational changes in Treg responses. 
Amino Acids and Treg Differentiation 
There are numerous features of the maternal metabolic environment 
that might favour enhanced Treg function. Maternal hypoaminoacidemia 
presents early in pregnancy and persists throughout gestation [12,23,24]. 
Amino acid deprivation can influence Treg differentiation and has been 
highlighted by the induction of a Treg phenotype during tryptophan 
starvation [47]. Tryptophan depletion and the immunoregulatory 
tryptophan catabolite kynurenine modulate FoxP3 expression through 
general control nonderepressible (GCN)-2 kinase activation and TGF-β 
signalling to induce a regulatory phenotype [47]. Plasma tryptophan levels 
are decreased during the 2nd and 3rd trimesters, decreasing as pregnancy 
progresses [48], which might suggest that the maternal circulation provides 
a favourable microenvironment for differentiation towards Treg cells. 
Although kynurenine levels in maternal plasma remain stable during 
pregnancy, the increase in kynurenine to tryptophan ratio with each 
trimester [48] could further promote the induction of CD4+/FoxP3+ T cells. 
Notably, this scenario very much reflects our focus on the changes that occur 
peripherally in pregnant women especially as pregnancy progresses. Local 
metabolic changes within the early pregnant uterus that might underpin 
pregnancy-favouring behaviours of Treg cells and other key effectors of 
implantation and placentation success such as decidual NK cells remain to 
be established. Similarly, perturbations in these that might then link to 
adverse pregnancy outcomes such as miscarriage remain to be elucidated. 
The availability of other essential amino acids can also influence 
FoxP3+ Treg cell differentiation from CD4+ T cells and the concentration of 
TGF-β required for differentiation is lower in conditions of essential amino 
acid deprivation [49]. Of the essential and conditionally-essential amino 
acids that drive FoxP3 induction at limited concentrations in synergy with 
TGF-β, four have reduced plasma concentrations during pregnancy—
valine, arginine, phenylalanine and tryptophan [50]. Under conditions of 
amino acid deprivation, mechanistic target of rapamycin (mTOR) 
regulates differentiation of CD4+ T cells to FoxP3+ induced Treg (iTreg) cells 
[49,51]. Inhibition of mTOR favours Treg cell differentiation, as mTOR 
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activity limits FoxP3 induction by key transcription factors SMAD and 
FOXO. TGF-β-induced SMAD3 and SMAD4 function and nuclear 
localisation of FOXO1 and FOXO3 are inhibited by mTORC1 and mTORC2 
respectively [52]. The activation of both mTORC1 and mTORC-2 is 
controlled directly by extracellular amino acids [53,54]. Indeed, essential 
amino acid deprivation reduces S6 phosphorylation in CD4+ T cells which 
then increases Treg cell differentiation [49]. Increased TGF-β 
concentrations in maternal serum during pregnancy [55] could also play 
a significant contribution towards Treg induction, especially when 
coupled with hypoaminoacidemia. 
Additionally, reduced levels of glutamine can also promote Treg 
differentiation from CD4+ T cells through inhibition of mTOR [56,57]. The 
effects of glutamine deprivation on mTOR activity can be rescued by the 
addition of α-ketoglutarate (α-KG), the product of glutaminolysis, therefore 
it is possible that this pathway underpins the modulation of mTOR by 
glutamine [56]. Given that the same restorative effect of α-KG was not 
observed in human iTreg cells [57], glutamine deprivation might also 
influence differentiation via alternative mechanisms. α-KG can further 
regulate Treg differentiation from CD4+ T cells through epigenetic 
modification of FoxP3 [58]. Hypermethylation within the Treg-specific 
demethylated region of the FoxP3 gene by 2-hydroxyglutarate, derived 
from α-KG, inhibits the expression of the FoxP3+ Treg phenotype [58]. 
Therefore, glutamine-deprived conditions would limit the availability of 
α-KG for conversion to 2-hydroxyglutarate and would maintain the 
demethylated status of the FoxP3 Treg-specific region, allowing its 
transcription and the consequent differentiation to Treg cells. Glutamine 
could also affect Treg differentiation from CD4+ T cells independent of 
glutaminolysis as inhibition of glutaminase, responsible for the 
conversion of glutamine to glutamate, does not induce the differentiation 
of Treg cells [59]. Plasma glutamine levels are reduced during the third 
trimester, whilst there is also a trimester-by-trimester decrease in the 
availability of branched chain amino acids (BCAA) that can act as a 
nitrogen pool for glutamine synthesis [50,60]. Glutamine uptake in CD4+ T 
cells is also required for leucine uptake via SLC7A5-CD98 amino acid 
transporter [61]. Leucine import results in activation of mTORC1, 
favouring differentiation towards other non-Treg subsets [61]. Decreased 
extracellular glutamine availability, as seen in pregnancy, could therefore 
limit leucine-mediated mTOR activity to skew towards a regulatory 
phenotype. Trimestral decreases in plasma leucine [50] could further 
hamper T cell mTOR activation and favour induction of Tregs. Thus, the 
amino acid-depleted environment of the maternal circulation during 
pregnancy potentially favours Treg cell differentiation. 
Fatty Acids and Treg Differentiation 
Fatty acid (FA) metabolism also plays an important role in controlling 
the fate of Treg cells and the enhanced efflux of lipid breakdown products 
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from maternal adipose tissue during the third trimester could support 
Treg cell expansion. Exogenous FA uptake by iTreg cells allows sustained 
proliferation and favours a regulatory phenotype [62]. iTreg cells are less 
dependent on acetyl-CoA carboxylase (ACC)1 for their development and 
can instead convert exogenous FAs into palmitate for phospholipid 
synthesis [62]. ACC1 inhibition and its effect on de novo FA synthesis does 
not affect iTreg development and promotes differentiation towards a 
regulatory lineage [62]. In particular, the oxidation of FAs taken up by 
CD4+ T cells is important for their development as iTreg cells—addition of 
FAs alone enhances differentiation towards the regulatory lineage whilst 
addition together with TGF-β further skews differentiation [63]. 
Underlying this process are the actions of both mTOR and AMP-activated 
protein kinase (AMPK)—reduced mTOR activity and heightened AMPK 
activity enhancing lipid metabolism which in turn increases the 
generation of CD4+/FoxP3+ T cells [63]. Consequently, pharmacological 
activators of AMPK such as metformin and 5-aminoimidazole-4-
carboxamide ribonucleotide (AICAR) are capable of enhancing Treg 
differentiation [63,64]. Inhibiting carnitine palmitoyltransferase 1a 
(CPT1a), the rate controlling enzyme of long-chain FA oxidation, with 
etomoxir blocks Treg differentiation from CD4+ T cells and outlines the 
importance of lipid oxidation [63]. Indeed, direct activation of AMPK by 
AICAR promotes Treg differentiation from CD4+ T cells through increased 
mitochondrial biogenesis and FA uptake and depends on the latter to exert 
its effect on differentiation [64]. However, emerging understanding of the 
off-target effects of etomoxir need to be taken into account when 
interpreting these data [65]. The metabolic sensor LKB1, upstream of 
AMPK, has also been identified as an important regulator of T cell 
metabolism and survival [66,67]. Compromised OXPHOS and ATP 
production upon LKB1 deletion ultimately resulted in reduced Treg 
numbers [66,67]. However, it is understood that LKB1 function in Treg 
cells occurs independently of conventional AMPK pathways and instead 
mediates MAPK signalling [66]. 
Short-chain FAs (SCFAs) also promote Treg differentiation [68]. SCFAs 
polarise CD4+ T cells towards a regulatory phenotype through inhibition of 
the JNK1 and the p38 pathway [68]. Increasing levels of the SCFA β-
hydroxybutyrate have been reported across pregnancy [50]. The sodium salt 
of butyrate can regulate the Th17/Treg balance to favour CD4+/FoxP3+ Treg 
cells [69]. Nuclear translocation and activation of the Nrf-2/HO-1 pathway is 
critical in sodium butyrate-mediated modulation of Th17 differentiation and 
the reciprocal increase of CD4+/FoxP3+ T cells [69]. Additionally, butyrate can 
act directly on peripheral and splenic naïve CD4+ T cells to enhance their 
differentiation to FoxP3+ Treg cells by stabilising the acetylation of the critical 
transcription factor FoxP3 [70,71]. The SCFA propionate can act on CD4+ T 
cells in the same manner as butyrate and presents an alternative method 
through which SCFAs can regulate Treg differentiation [70]. As maternal 
plasma is enriched with SCFAs [50], it is plausible that this could contribute 
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to the expanded Treg population observed during pregnancy. The 
contribution of the maternal gut microbiome to these SCFAs is beyond the 
scope of this review but there is immense interest in the relationship 
between the maternal microbiota and immune programming of the 
offspring [72]. Together, our current understanding of both maternal 
metabolism during pregnancy and the role of metabolism underlying Treg 
differentiation would suggest that the maternal circulation provides a highly 
favourable environment for Treg cells—especially during the third 
trimester. Given that this population of T cells is increased during pregnancy, 
it is possible that this occurs due to the amino acid-deprived landscape of 
maternal peripheral blood, and is further supplemented by the increased 
appearance of FAs during the third trimester.  
Hormonal Regulation of Treg Function 
Further to the aforementioned effect that pregnancy hormones have 
on Treg cells, metabolic hormones such as leptin can also influence Treg 
responses. Treg cells express higher amounts of the leptin receptor (ObR) 
than other T cell subsets, which suggests that leptin might have a greater 
influence in shaping their functional output [73]. Indeed, leptin negatively 
regulates Treg proliferation, but does not have a significant effect on the 
suppressive capacity of these cells [73]. The absence of leptin, or chronic 
blockade of its receptor, increases Treg cell numbers which has led to 
resistance in models of autoimmune diseases [73,74]. Leptin also plays 
some important roles during pregnancy—recombinant leptin improved 
conception in infertile mice, whilst regulatory roles in 
immunomodulation, angiogenesis and nutrient transport have been 
described in the placenta [75,76]. Usually produced in adipose tissue, 
placenta-derived leptin emerges as a novel pregnancy hormone and 
during the second and third trimester plasma leptin levels become 
elevated including a contribution of the placenta as a pregnancy-specific 
source of leptin [77,78]. Leptin resistance develops during the second 
trimester and has a role in supporting the growth of the fetus [79,80], 
whilst maternal obesity has been associated with further leptin resistance 
in the placenta [81]. While the leptin-rich environment that presents 
during the second and third trimester might be expected to contradict the 
known effects of leptin on Treg number, the accompanying leptin 
resistance would favour increased Tregs [73,74], although we do not know 
if this leptin resistance extends to the immune system and more 
specifically Treg cells. 
Fatty Acids and Treg Function 
Metabolism not only dictates Treg differentiation but also controls Treg 
cell effector function. Thymic Treg (tTreg) cells engage glycolysis upon 
activation through TNF receptor 2 co-stimulation, which is required for 
their expression of key transcription factors such as FoxP3, as well as their 
suppressive function [82]. As maternal plasma glucose levels are limited 
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during pregnancy [5], our focus has shifted to other elements of 
metabolism, such as fatty acids and amino acids, whose changes are more 
profound during pregnancy and are key contributors to cellular metabolic 
pathways. Treg cells with significantly reduced lipid synthesis have 
reduced survival and attenuated immunosuppressive function [66,67,83]. 
Upon stimulation through PD-1 and CTLA-4 and induction of FoxP3 
expression, iTreg cells prepare for effector function by lowering the rate 
of glycolysis whilst concomitantly increasing oxidative metabolism and FA 
oxidation [84]. iTreg cells fail to upregulate Myc upon stimulation which 
results in restrained glycolysis [85]. Inhibition of either OXPHOS or FA 
oxidation diminishes the suppressive function of iTreg cells and thus 
underlines the importance of metabolism in directing a Treg response 
[85,86]. In a mixed population of iTreg and tTreg cells, uptake and 
oxidation of exogenous FA contributed to OXPHOS and favoured Treg 
stability [87]. Inhibition of the mevalonate pathway through deletion of 
HMG-CoA reductase also causes defective Treg cell function in both iTreg 
and tTreg cells and culminates in an autoimmune disease phenotype 
[83,88,89]. LKB-1 deficient iTreg cells produce less IL-10 and have 
decreased surface expression of effector molecules such as CTLA-4, PD-1, 
CD39 and CD73, instead enhancing their production of inflammatory 
cytokines which ultimately results in failure to inhibit autoimmunity [83]. 
The mevalonate pathway is impaired in LKB-1 deficient iTreg cells and 
inhibition of HMG-CoA reductase induces a similar inflammatory 
phenotype to that of LKB1 deletion [83]. Suppressive iTreg function is 
restored upon treatment with mevalonate and geranylgeranyl 
pyrophosphate (GGPP) [83]. Increased plasma lipid concentrations, as seen 
during late pregnancy, would enhance substrate availability to these 
pathways and might explain enhanced gestational Treg cell function as 
pregnancy progresses. 
Recently, fatty acids have emerged as key regulators of Treg cell 
mitochondrial health [90,91]. Expression of CD36, a fatty acid translocase, 
is required for the immunosuppressive function and survival of 
intratumoural Treg cells [90]. CD36 also modulates the mitochondrial 
fitness of both intratumoural Treg cells and iTreg cells and supports their 
metabolic adaptation within the microenvironment [90]. Lipid chaperones 
responsible for the uptake and intracellular transport of lipids, such as 
fatty acid binding protein 5 (FABP5) are also implicated in maintaining 
mitochondrial health in iTreg cells [91]. Inhibition results in impaired 
oxidative respiration, loss of cristae structure and ablated lipid 
metabolism [91]. Under these circumstances there was a reduction in iTreg 
cell number, however, suppressive function was augmented through the 
release of mitochondrial DNA caused by mitochondrial dysfunction [91]. 
The resulting cGAS-STING signalling and subsequent type I IFN signalling 
promote IL-10 expression and drive suppressive Treg function [91]. 
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Amino Acids and Treg Function 
Amino acids play a more reserved role in orchestrating suppressive Treg 
function. Glutamine depletion produces iTreg cells with suppressive 
function such as IL-4 production, however, these cells also express pro-
inflammatory cytokines IL-17 and IFNγ [57]. This might suggest that 
balanced amino acid levels are required for successful regulatory function. 
Collectively, these data support the hypothesis that maternal immunological 
adaptation is secondary to changes in metabolism and energy substrate 
utilisation. It is important to note that the majority of the studies discussed 
in this manuscript analyse the fate and function of iTreg cells, with those 
concerning tTreg cells highlighted. Whether the concepts addressed 
throughout this section apply to both iTreg and tTreg cells is not known, but 
would be an important factor to consider in any future research. It is also 
important to acknowledge that other Treg populations, such as those 
localised at the decidua, might be differentially affected compared to the 
peripheral blood Treg cells discussed. For example, little is known about that 
the metabolic environment at the materno-fetal interface, therefore 
understanding the effect that this local metabolic environment might impose 
on Treg cells could be fundamental to elucidating reduced Treg numbers in 
women with recurrent pregnancy loss and other adverse pregnancy 
outcomes. As yet there are no experimental data to support this hypothesis 
other than the coalignment of what we know about changing Treg cell 
number in pregnancy and the changes to substrate availability. Detailed 
investigation of the metabolic changes to Treg cells that accompany 
pregnancy normally and in adverse pregnancy outcomes such as 
miscarriage and preeclampsia are certainly warranted.  
TH2 CELLS 
In addition to Treg cells, there is an increase in the activity of Th2 cells 
during pregnancy. T helper (Th) cells have been long characterised by their 
cytokine profile and this allows their classification into different subsets 
[92]. Th2 responses are characterised by the release of IL-4, IL-5, IL-9 and IL-
3. Naïve CD4+ T cells differentiate to a Th2 phenotype through activation of 
signal transducer and activator of transcription (STAT)6 and GATA3. 
Increased Th2 cell activity occurs at both the fetal-placental interface and in 
peripheral blood and is measured as a ratio of the activity of Th2 cells 
compared to Th1 cells. During pregnancy, there is an increase in the 
secretion of type 2 immune cytokines—so origins possibly other than T cells 
such as IL-4, with a relative increase compared to cytokines such as IFNγ 
and IL-2 [93,94]. This likely occurs due to changes at the protein level that 
reflect increased IL-4 mRNA expression in T cells whilst IFNγ mRNA 
expression is decreased [95]. This ratio remains throughout gestation and 
reverts to non-pregnant levels postpartum [96,97]. Some studies suggest that 
Th2 activity declines as early as the latter stages of labour [98]. Although 
enhanced Th2 activity has been demonstrated throughout human 
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pregnancy, the complete absence of a Th2 response does not affect allogenic 
mouse pregnancy, which suggests that Th2 cells are not essential in 
maintaining the materno-fetal tolerance—at least in mice [99]. 
Amino Acids and Th2 Responses 
Global changes in maternal metabolism also could underpin the Th2 
biased responses that are observed during pregnancy as metabolic 
pathways are key regulators of both Th2 differentiation and function. 
Characteristic reductions in plasma amino acid concentrations during 
pregnancy, particularly reduced glutamine [12,50], potentially tips the 
Th1/Th2 ratio in favour of Th2 cells. Treatment of PBMCs with high 
concentrations of glutamine in vitro impairs Th2-like responses through 
suppression of IL-10 production and augmenting IFNγ production [100]. 
These changes are realised physiologically as dietary glutamine shapes the 
Th1/Th2 balance towards Th1 cells over Th2 cells, reflected by increased 
IL-2 production and decreased IL-4 production [101]. In fact, Th2 cells are 
not dependent on glutamine and rather have improved function in its 
absence [61]. Deletion of ASCT2 enhanced the generation of Th2 cells, 
increasing the expression of both GATA3 and IL-4 [61]. A possible 
mechanism of action for glutamine-mediated T cell regulation is its 
inhibition of cytosolic phospholipase A2 activity [102]. Th2 cytokine 
production is reduced in the presence of glutamine which culminates in 
failure to recruit neutrophils and eosinophils to inflamed airways [102]. 
Cytosolic phospholipase A2 is important in facilitating the release of 
arachidonic acid from glycerophospholipids for their incorporation into 
Th2-related inflammatory mediators. 
The contribution of tryptophan metabolism to Th2 function has already 
been demonstrated in the setting of murine pregnancy [103]. Decreased 
tryptophan metabolism in the uterus balances the Th1/Th2 ratio in the 
favour of Th1 cells which increases the likelihood of pregnancy failure 
[103]. In human pregnancy, low levels of tryptophan but maintained levels 
of its metabolites such as kynurenine suggest increased tryptophan 
metabolism and utilisation of the metabolites [48] and would present a 
Th2 favouring milieu. The absence of tryptophan catabolising enzymes in 
the lung impaired Th2-mediated inflammatory airway responses with 
reductions in IL-5, IL-13 and IL-4 production [104]. The activity of the 
tryptophan-catabolising enzyme indoleamine-2,3-dioxygenase (IDO) is 
thought to be increased during pregnancy, playing an important role in 
immune activation [105]. Additionally, tryptophan catabolism deficiency 
had less of an impact on Th1 responses [104]. Interestingly, metabolites of 
the kynurenine pathway cause apoptosis of Th1 but do not impact Th2 
survival [47]. Together, these data suggest that increased flux through 
tryptophan catabolism pathways supports Th2 responses in the Th1/Th2 
balance. Thus, the amino acid landscape of pregnancy could support the 
Th2-skewed Th1/Th2 ratio that is observed. 
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Fatty Acids and Th2 Responses 
Lipid metabolism is also implicated in Th2 cell expansion and function. 
Inhibition of ACC1 impairs Th2 induction and underlines the importance 
of lipid synthesis in mediating Th2 responses [62,106]. Lipid pathways also 
play an important role in Th2 development. Upon stimulation and 
subsequent activation of CD4+ T cells, FA uptake is increased and is 
essential for successful proliferation [106]. Lipid synthesis through ACC1 
was also important for proliferation and made a significant contribution 
to glycolysis [106].  
Peroxisome proliferator-activated receptor (PPAR)γ—the master 
regulator of lipid metabolism and storage—entwines cellular metabolism 
with Th2 effector function. PPARγ inhibition inflicted the same metabolic 
and functional effects on CD4+ T cells as ACC1 inhibition, suggesting that 
PPARγ-mediated metabolic reprogramming directs the activation of Th2 
cells [106]. Gene expression analysis has revealed that activated Treg cells 
are enriched in genes associated with lipid metabolism [107]. There are more 
PPARγ binding sites on open chromatin at loci that facilitate enhanced 
expression of the lipid-associated target genes needed for glucose 
metabolism and promoting Th2 functions such as recruitment of eosinophils 
to inflamed airways [107]. Included in the target genes for PPARγ binding 
are IL-5 and IL-13, and key Th2 transcription factor GATA3 [108]. Th2 cells 
lacking PPARγ failed to mount a Th2 response to allergic challenge in the 
airways of mice [109]. PPARγ deletion reduced the production of IL-5 and IL-
13 by Th2 cells and reduced the presence of eosinophils and mucus-secreting 
goblet cells, culminating in an impaired pathogenic response [109]. Similar 
responses were also seen in other mouse models of allergic airway 
inflammation and H. polygyrus infection [109,110], emphasising the 
importance of PPARγ in protective immunity. IL-33 plays a critical role in 
PPARγ signalling in Th2 cells. IL-33R ligation upregulates the expression of 
PPARγ, which itself can upregulate the expression of IL-33R subunit ST2, 
creating a positive feedback loop [109,110]. 
The role of PPARγ activity in IL-4 production remains unclear, with 
reports that it can enhance [110], suppress [111] or have no effect [109] on 
IL-4 expression. It has also been proposed that PPARγ can influence Th2 
response indirectly via the actions of dendritic cells [110]. Expression of 
PPARγ by dendritic cells is controlled by IL-4 and IL-33 and drives 
polarisation of T cells towards a Th2 phenotype [110]. Production of IL-9 
also has been associated with PPARγ, giving rise to a subset of T cells that 
also produce increased amounts of IL-5 and IL-13 [112]. However, 
activation by TGF-β and IL-4, which enhance the expression of PPARγ, 
promotes a Th9 phenotype where Th2 cytokines are downregulated [112]. 
The ability of PPARγ to influence metabolic pathways likely underpins its 
role in controlling Th2 functions. In the absence of PPARγ, FA uptake was 
attenuated with mediators such as FABP5 downregulated [106], whilst 
carbohydrate synthesis, metabolite transport, lipid storage and lipolysis 
were also all affected [109]. 
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The influence of SCFAs on Th2 function remains unclear. Early work 
suggests that SCFAs have a negative effect on Th2 responses, with long-
term defects on IL-5 and IL-13 production upon propionate treatment 
[113]. However, recently various C2–4 SCFAs have been shown to increase 
the expression of IL-5 following FFAR3-mediated signalling [114]. In vivo, 
SCFA treatment materialises as enhanced Th2 cytokine production and a 
consequent increase in eosinophil recruitment [114]. The hyperlipidemic 
maternal phenotype appears tailored for enhanced Th2 cell function 
(Figure 3). Increased lipid availability would provide the substrates 
necessary for enhanced type 2 cytokine production, as is seen in normal 
pregnancy, and perhaps explains the mechanisms underpinning the Th2 
biased responses seen during pregnancy. However, as for Tregs above 
there are no direct data to support this postulated, but such studies 
warrant investigation. 
 
Figure 3. The potential effect of maternal metabolism on Th2 proliferation and function. Peroxisome 
proliferator-activated receptor (PPAR)-γ is central to T helper 2 (Th2) cell glycolytic and oxidative 
metabolism, function and proliferation. Pregnancy is associated with increased circulating fatty acid (FA) 
levels. Enhanced lipid metabolism, such as increased fatty acid uptake, oxidation and synthesis, likely 
influences PPARγ activity to increase Th2 proliferation. PPARγ also promotes ST2 expression to increase the 
expression of Th2-related cytokines such as IL-9, IL-13, IL-15 and possibly IL-4. α-KG, α-ketoglutarate; FA, 
fatty acid; IL, interleukin; TCA, tricarboxylic acid; TH2, T helper 2 cell. 
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CONCLUDING REMARKS 
Metabolic adaptation during pregnancy is essential for successful fetal 
growth and development. This is achieved through many tightly regulated 
processes occurring as a result of the overarching increase in insulin 
resistance as gestation progresses. The effect of these processes on tissues 
such as the liver, adipose and skeletal muscle are well described, however 
it is unknown how these processes might affect the immune system. 
Immune plasticity is required during pregnancy, both to ensure tolerance 
of the semi-allogenic fetus and to protect mother and fetus from infection. 
Metabolism has emerged as a central regulator of immune cell phenotype 
and function, therefore it is increasingly likely that maternal 
immunological adaptation is governed by wider metabolic changes 
characteristic of gestation. Understanding the pathways underlying 
changes in immunometabolism and immune cell fate and function could 
reveal potential therapeutic targets to alleviate disease severity during 
pregnancy, benefitting the long-term health of both the mother and 
newborn. This will also reveal the spectrum of normal immunometabolic 
programming and plasticity in humans that could be harnessed for 
therapeutic benefit in disease settings outside of pregnancy. 
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